16
Participants
Start Date
August 31, 2008
Primary Completion Date
June 30, 2011
Study Completion Date
June 30, 2011
PF-04217903
Escalating doses of PF-04217903 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 50 mg BID to 1000 mg BID. A cycle is considered to be 21 days
Pfizer Investigational Site, Detroit
Pfizer Investigational Site, Chicago
Pfizer Investigational Site, Aurora
Pfizer Investigational Site, Boston
Pfizer Investigational Site, Boston
Pfizer Investigational Site, Boston
Lead Sponsor
Pfizer
INDUSTRY